Novel inhibitors of PARP1 and PARP14: design, synthesis, and potentiation of cisplatin efficacy in cancer DOI
Caleb M. T. Kam, Amanda L Tauber, Matthew Zunk

et al.

Future Medicinal Chemistry, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 24

Published: Dec. 18, 2024

Poly(ADP-ribose) polymerase (PARP) is a superfamily of enzymes involved in cell survival. Both PARP1 and PARP14 are overexpressed malignancies. No clinically approved inhibitors available, generally nonspecific, resulting need for more diverse library selective inhibitors.

Language: Английский

Computational Design and Structural Insights into Quinazoline-Based Lead Molecules for Targeting PARP10 in Cancer Therapy DOI

Revathi Gnanavelou,

Manikandan Jayaraman,

Jeyaraman Jeyakanthan

et al.

Journal of Molecular Graphics and Modelling, Journal Year: 2025, Volume and Issue: 137, P. 109005 - 109005

Published: March 3, 2025

Language: Английский

Citations

0
Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability DOI
Juan Xu,

Anmin Zhao,

Danni Chen

et al.

European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 266, P. 116160 - 116160

Published: Jan. 18, 2024

Language: Английский

Citations

3
Exploring the structural-activity relationship of hexahydropyrazino[1,2-d]pyrido[3,2-b][1,4]oxazine derivatives as potent and orally-bioavailable PARP7 inhibitors DOI
Silong Zhang, Yu Zhang, Ziwei Wang

et al.

European Journal of Medicinal Chemistry, Journal Year: 2023, Volume and Issue: 261, P. 115836 - 115836

Published: Oct. 9, 2023

Language: Английский

Citations

2
Novel inhibitors of PARP1 and PARP14: design, synthesis, and potentiation of cisplatin efficacy in cancer DOI
Caleb M. T. Kam, Amanda L Tauber, Matthew Zunk

et al.

Future Medicinal Chemistry, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 24

Published: Dec. 18, 2024

Poly(ADP-ribose) polymerase (PARP) is a superfamily of enzymes involved in cell survival. Both PARP1 and PARP14 are overexpressed malignancies. No clinically approved inhibitors available, generally nonspecific, resulting need for more diverse library selective inhibitors.

Language: Английский

Citations

0